BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 27939230)

  • 21. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
    Semb AG; Holme I; Kvien TK; Pedersen TR
    Rheumatology (Oxford); 2011 Feb; 50(2):324-9. PubMed ID: 20884656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
    Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
    BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial.
    Newman JD; Alexander KP; Gu X; O'Brien SM; Boden WE; Govindan SC; Senior R; Moorthy N; Rezende PC; Demkow M; Lopez-Sendon JL; Bockeria O; Pandit N; Gosselin G; Stone PH; Spertus JA; Stone GW; Fleg JL; Hochman JS; Maron DJ
    Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006002. PubMed ID: 31718297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg.
    Li J; Somers VK; Gao X; Chen Z; Ju J; Lin Q; Mohamed EA; Karim S; Xu H; Zhang L
    JAMA Netw Open; 2021 Feb; 4(2):e2037554. PubMed ID: 33595663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components.
    Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC
    Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relation between baseline LDL-cholesterol and cardiovascular outcomes in high cardiovascular risk hypertensive patients: A post-hoc SPRINT data analysis.
    Nguyen LS; Procopi N; Salem JE; Squara P; Funck-Brentano C
    Int J Cardiol; 2019 Jul; 286():159-161. PubMed ID: 30685099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
    Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
    Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
    Collins R; Armitage J; Parish S; Sleight P; Peto R;
    Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention.
    Lee EY; Yang Y; Kim HS; Cho JH; Yoon KH; Chung WS; Lee SH; Chang K
    Atherosclerosis; 2018 Dec; 279():1-9. PubMed ID: 30359786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the statin escape phenomenon on long-term clinical outcomes in patients with acute myocardial infarction: Subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS).
    Ota T; Ishii H; Suzuki S; Shibata Y; Tatami Y; Harata S; Shimbo Y; Takayama Y; Tanaka A; Kawamura Y; Osugi N; Maeda K; Kondo T; Murohara T
    Atherosclerosis; 2015 Sep; 242(1):155-60. PubMed ID: 26188539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.
    Liao KP; Liu J; Lu B; Solomon DH; Kim SC
    Arthritis Rheumatol; 2015 May; 67(8):2004-10. PubMed ID: 25917955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association of blood lipid parameters variability with ischemic stroke in hypertensive patients.
    Huang YQ; Liu L; Liu XC; Lo K; Tang ST; Feng YQ; Zhang B
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1521-1532. PubMed ID: 33810958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
    Bauters C; Tricot O; Lemesle G; Meurice T; Hennebert O; Farnier M; Lamblin N
    Arch Cardiovasc Dis; 2018 Nov; 111(11):634-643. PubMed ID: 29198936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of left ventricular mass change during treatment of hypertension.
    Devereux RB; Wachtell K; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris K; Aurup P; Dahlöf B
    JAMA; 2004 Nov; 292(19):2350-6. PubMed ID: 15547162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Visit-to-Visit Variability in Systolic Blood Pressure on Cardiovascular Outcomes in Korean National Health Insurance Service-National Sample Cohort.
    Choi S; Shin J; Choi SY; Sung KC; Ihm SH; Kim KI; Kim YM
    Am J Hypertens; 2017 Jun; 30(6):577-586. PubMed ID: 28052880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: A 5-year follow-up study.
    Boey E; Gay GM; Poh KK; Yeo TC; Tan HC; Lee CH
    Atherosclerosis; 2016 Jan; 244():86-92. PubMed ID: 26595903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.